Business
Medicure Announces Settlement of Holdback Dispute from Apicore Sale
Medicure Announces Settlement of Holdback Dispute from Apicore Sale Canada NewsWir...
About this update from Medicure Inc.
[{"type":"text","content":"\n\n\n\nMedicure Announces Settlement of Holdback Dispute from Apicore Sale\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nWINNIPEG, Dec. 5, 2019\n\n\n\nWINNIPEG, Dec. 5, 2019 /CNW/ - Medicure Inc. (\"Medicure\" or the \"Company\") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today announced that it has reached a settlement agreement with the purchaser of Medicure's interests in Apicore with respect to the amounts heldback under the Apicore sale agreement. A settlement agreement was reached under which Medicure will receive a net payment of US$5.1 million in relation to the holdback.\nAbout Medicure\nMedicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the Company is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection, ZYPITAMAGTM (pitavastatin) tablets and the ReDS™ device in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. For more information on Medicure please visit www.medicure.com.\nTo be added to Medicure's e-mail list, please visit:  http://medicure.mediaroom.com/alerts\nNeither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. \n View original content:http://www.prnewswire.com/news-releases/medicure-announces-settlement-of-holdback-dispute-from-apicore-sale-300970400.html\nSOURCE Medicure Inc.\n\n\n\nView original content: http://www.newswire.ca/en/releases/archive/December2019/05/c2407.html\n\n\n\n\nJames Kinley, Chief Financial Officer, Tel. 888-435-2220, Fax 204-488-9823, E-mail: [email protected], www.medicure.comCopyright CNW Group 2019","length":3620,"tagName":"div"}]